(Q41441206)

English

Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials

scientific article published on 19 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 September 2017

0 references

Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials (English)

1 reference

Europe PubMed Central

30 September 2017

0 references

12

object named as

Martin B Leon

1 reference

Europe PubMed Central

30 September 2017

author name string

Zhan Gao

1

1 reference

Europe PubMed Central

30 September 2017

Ruiyan Zhang

2

1 reference

Europe PubMed Central

30 September 2017

Bo Xu

3

1 reference

Europe PubMed Central

30 September 2017

Yuejin Yang

4

1 reference

Europe PubMed Central

30 September 2017

Changsheng Ma

5

1 reference

Europe PubMed Central

30 September 2017

Hui Li

6

1 reference

Europe PubMed Central

30 September 2017

Shaoliang Chen

7

1 reference

Europe PubMed Central

30 September 2017

Yaling Han

8

1 reference

Europe PubMed Central

30 September 2017

Zuyi Yuan

9

1 reference

Europe PubMed Central

30 September 2017

Alexandra J Lansky

10

1 reference

Europe PubMed Central

30 September 2017

Changdong Guan

11

1 reference

Europe PubMed Central

30 September 2017

Runlin Gao

13

1 reference

Europe PubMed Central

30 September 2017

TARGET Investigators

14

1 reference

Europe PubMed Central

30 September 2017

publication date

19 February 2015

1 reference

Europe PubMed Central

30 September 2017

Catheterization and Cardiovascular Interventions

1 reference

Europe PubMed Central

30 September 2017

85 Suppl 1

1 reference

Europe PubMed Central

30 September 2017

734-743

1 reference

Europe PubMed Central

30 September 2017

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Coronary stents: looking forward

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

First nine-month complete invasive assessment (angiography, IVUS, and OCT) of the novel NEVO sirolimus-eluting stent with biodegradable polymer

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the rand

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions

1 reference

https://api.crossref.org/works/10.1002%2FCCD.25861

21 January 2018

Identifiers

10.1002/CCD.25861

1 reference

Europe PubMed Central

30 September 2017

1 reference

Europe PubMed Central

30 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41441206&oldid=2097751933"